Williamg Wierda News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology and hematology portfolio at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

United statesSouth koreaPushkar muthaMariat bourlonTycel jovelle phillipsTony mokLin wangPeter robert galleCharlene mantiaMarc hoffmannEric christensonSuzanne trudelManali kirtikumar kamdarGuillermo garcia maneroMartin reckTina cascone

Lilly s Jaypirca blazes leukemia trail with FDA nod, fast confirmatory trial filing

Lilly s Jaypirca blazes leukemia trail with FDA nod, fast confirmatory trial filing
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

United statesLilly jaypircaVan naardenBeigene brukinsaWilliamg wierdaAbbviejj imbruvicaRoche venclextaJake van naardenUniversity of texas md anderson cancer centerAmerican society for hematologyEli lillyCancer centerAmerican societyFierce biotech

FDA Approves Pirtobrutinib for Previously Treated CLL/SLL

The approval is the second this year for the reversible, highly selective kinase inhibitor following a January approval in mantle cell lymphoma.

United statesEli lillyWilliamg wierdaUniversity of texas md anderson cancer centerDrug administrationCancer centerMantle cell lymphomaSmall lymphocytic lymphomaMall lymphocytic lymphoma sllMalignant lymphomaChronic lymphocytic leukemia lymphoid cll leukaemiaAlignant neoplasiaAlignant neoplasmUs food and drug administration

FDA Approves Pirtobrutinib For Treatment of Adult Patients With CLL, SLL

Pirtobrutinib is the first and only non-covalent BTK inhibitor to be approved by the FDA and is indicated for adult patients who already received at least 2 prior lines of therapy.

Williamg wierdaJacob van naardenBrian koffmanEli lillyMd anderson cancer centerDepartment of leukemiaUniversity of texasCancer center

FDA Approves Jaypirca for Pretreated CLL, SLL

The Food and Drug Administration approved Jaypirca for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who received two or more lines of therapy.

United statesBrian koffmanWilliamg wierdaEli lillyUniversity of texas md anderson cancer centerDrug administrationCancer centerNew treatments areChronic lymphocytic